Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

Trial Profile

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Durvalumab (Primary) ; Pralatrexate (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Apr 2020 Results (n=12) of preliminary clinical data from two clinical studies: phase 1 trial NCT03240211 and phase 1/2 trial NCT03161223 were presented at the 111th Annual Meeting of the American Association for Cancer Research - I
    • 22 Jan 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.
    • 13 May 2019 Planned End Date changed from 30 Jun 2020 to 1 Feb 2021.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top